Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM2-DM1)

NCT06667453 is registered in ClinicalTrials.gov with PepGen Inc as lead sponsor.

NCT NCT06667453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06667453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM2-DM1)
Lead sponsor
PepGen Inc
Phase
Phase 2
Overall status
Recruiting
Start date
December 10, 2024
Completion date
March 31, 2027
Enrollment
24 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

myotonic dystrophy 1